BioLife Solutions news

Company is under investigation for potential securities law violations and fiduciary duty breaches in its sale to Repligen, with concerns about insider benefits and limited competing offers.

The article is a straightforward announcement of upcoming earnings results and conference call details. There is no new financial data, business developments, or forward-looking statements that would indicate positive or negative sentiment. It is purely informational about when and how investors can access the Q1 2026 results.

The company received industry recognition from INTERPHEX for addressing a documented market need in CGT manufacturing. The award validates their product's solution to real containment challenges, and the product launch in 2025 demonstrates active commercialization efforts in a growing market segment.

Strong revenue growth of 29% YoY, improved profitability with Q4 net income of $2.1M vs. prior year loss, significant EBITDA margin expansion (28% in Q4 2025 vs. 18% in Q4 2024), strategic divestiture completed to focus on high-margin core business, and positive 2026 guidance with expected 17-20% growth and full-year GAAP profitability. Company demonstrates operational leverage and market leadership with ~70% market share in biopreservation media for CGT trials.

The company is expanding its product portfolio into a fast-growing market segment (cytokines) with projected mid-teens annual growth through 2030. The strategic partnership provides exclusive distribution rights to complementary products and positions BioLife to capture growth in the expanding CGT market.

Introduced CellSeal CryoCase in May 2024 addressing critical packaging integrity needs for extended transport chains, positioning company well in expanding cold chain logistics market.